Home / News / Worldwide Relapsed Chronic Lymphocytic Leukemia (CLL) Market Size, Share, Growth Trends, Key Players, Competitive Strategies and Forecasts 2016 – Acute Market Reports

Worldwide Relapsed Chronic Lymphocytic Leukemia (CLL) Market Size, Share, Growth Trends, Key Players, Competitive Strategies and Forecasts 2016 – Acute Market Reports

Acute Market Reports’s, ‘Relapsed Chronic Lymphocytic Leukemia (CLL) – Pipeline Review, H1 2016’, provides an overview of the Relapsed Chronic Lymphocytic Leukemia (CLL) pipeline landscape.

Browse Full Report Visit – http://www.acutemarketreports.com/report/relapsed-chronic-lymphocytic-leukemia-cll-pipeline-review-h1-2016

The report provides comprehensive information on the therapeutics under development for Relapsed Chronic Lymphocytic Leukemia (CLL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects.

Acute Market Reports’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Acute Market Reports’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Browse All Reports of This Category – http://www.acutemarketreports.com/category/healthcare-market

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Relapsed Chronic Lymphocytic Leukemia (CLL)
– The report reviews pipeline therapeutics for Relapsed Chronic Lymphocytic Leukemia (CLL) by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved Relapsed Chronic Lymphocytic Leukemia (CLL) therapeutics and enlists all their major and minor projects
– The report assesses Relapsed Chronic Lymphocytic Leukemia (CLL) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news related to pipeline therapeutics for Relapsed Chronic Lymphocytic Leukemia (CLL)

Reasons to buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand important and diverse types of therapeutics under development for Relapsed Chronic Lymphocytic Leukemia (CLL)
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Relapsed Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Get Complete Report @ Relapsed Chronic Lymphocytic Leukemia (CLL) – Pipeline Review, H1 2016

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Acute Market Reports Report Coverage 7
Relapsed Chronic Lymphocytic Leukemia (CLL) Overview 8
Therapeutics Development 9
Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) – Overview 9
Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) – Comparative Analysis 10
Relapsed Chronic Lymphocytic Leukemia (CLL) – Therapeutics under Development by Companies 11
Relapsed Chronic Lymphocytic Leukemia (CLL) – Therapeutics under Investigation by Universities/Institutes 13
Relapsed Chronic Lymphocytic Leukemia (CLL) – Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Relapsed Chronic Lymphocytic Leukemia (CLL) – Products under Development by Companies 17
Relapsed Chronic Lymphocytic Leukemia (CLL) – Products under Investigation by Universities/Institutes 20
Relapsed Chronic Lymphocytic Leukemia (CLL) – Companies Involved in Therapeutics Development 21
4SC AG 21
AbbVie Inc. 22
Astellas Pharma Inc. 23
Astex Pharmaceuticals, Inc. 24
AstraZeneca Plc 25
Boehringer Ingelheim GmbH 26
Bristol-Myers Squibb Company 27
Celgene Corporation 28
Cyclacel Pharmaceuticals, Inc. 29
Emergent BioSolutions Inc. 30
F. Hoffmann-La Roche Ltd. 31
Hutchison MediPharma Limited 32
ImmunoGen, Inc. 33
Immunomedics, Inc. 34
Incyte Corporation 35
Infinity Pharmaceuticals, Inc. 36
Innate Pharma S.A. 37
Juno Therapeutics Inc. 38
Karyopharm Therapeutics, Inc. 39
Les Laboratoires Servier SAS 40
LFB S.A. 41
Lymphocyte Activation Technologies, S.A. 42
Millennium Pharmaceuticals, Inc. 43
MorphoSys AG 44
Novartis AG 45
Oncternal Therapeutics, Inc. 46
Ono Pharmaceutical Co., Ltd. 47
Portola Pharmaceuticals, Inc. 48
Sanofi 49
TG Therapeutics, Inc. 50
Threshold Pharmaceuticals, Inc. 51
Tragara Pharmaceuticals, Inc. 52
Relapsed Chronic Lymphocytic Leukemia (CLL) – Therapeutics Assessment 53
Assessment by Monotherapy Products 53
Assessment by Combination Products 54
Assessment by Target 55
Assessment by Mechanism of Action 58
Assessment by Route of Administration 61
Assessment by Molecule Type 63
Drug Profiles 65
(INCB-039110 + INCB-040093) – Drug Profile 65
4SC-202 – Drug Profile 66
acalabrutinib – Drug Profile 68
ACP-319 – Drug Profile 71
afuresertib hydrochloride – Drug Profile 72
AGS-67E – Drug Profile 75
AT-7519 – Drug Profile 77
AZD-6738 – Drug Profile 80
BI-836826 – Drug Profile 82
BMS-986016 – Drug Profile 83
buparlisib hydrochloride – Drug Profile 84
CC-122 – Drug Profile 88
Cellular Immunotherapy for Chronic Lymphocytic Leukemia – Drug Profile 90

Latest Reports :

Amyotrophic Lateral Sclerosis – Pipeline Review, H1 2016

Relapsed Chronic Lymphocytic Leukemia (CLL) – Pipeline Review, H1 2016

Hepatitis B – Pipeline Review, H1 2016
About – Acute Market Reports :

Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements.We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends.

Our team consists of highly motivated market research professionals and they are accountable for creating the groundbreaking technology that we utilize in our search engine operations to easily recognize the most current market research reports online.
Contact Us : 
Chris Paul
ACUTE MARKET REPORTS
Office No 101, 1st Floor ,
Aditi Mall, Baner,
Pune, MH, 411045
India
Toll Free(US/CANADA): +1-855-455-8662
India: +91 7755981103
Email : sales@acutemarketreports.com
Website : http://www.acutemarketreports.com

Release ID: 4080

About Chris Paul

Check Also

400-400

Global Carbon Nanofiber Market Size, Share, Growth, Outlook, strategies and Forecast to 2016: Acute Market Reports

Notes: Production, means the output of Carbon Nanofiber Revenue, means the sales value of Carbon ...